Chemistry:Gefapixant
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Trade names | Lyfnua |
| Other names | MK-7264 |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C14H19N5O4S |
| Molar mass | 353.40 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough.[1] It acts as an antagonist of the P2RX3 receptor.[2][3][4]
It was approved for medical use in the European Union in September 2023.[1]
Medical uses
Gefapixant is indicated for the treatment of refractory or unexplained chronic cough.[1]
Society and culture
Names
It was named in honour of Geoff Burnstock.[5]
References
- ↑ 1.0 1.1 1.2 1.3 "Lyfnua EPAR". 29 September 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/lyfnua.
- ↑ "Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough". Pulmonary Pharmacology & Therapeutics 56: 75–78. June 2019. doi:10.1016/j.pupt.2019.03.006. PMID 30880151.
- ↑ "Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation". British Journal of Pharmacology 176 (13): 2279–2291. July 2019. doi:10.1111/bph.14677. PMID 30927255.
- ↑ "Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications". Expert Opinion on Therapeutic Patents 29 (12): 943–963. December 2019. doi:10.1080/13543776.2019.1693542. PMID 31726893.
- ↑ "The discovery and development of gefapixant". Autonomic Neuroscience 235: 102859. November 2021. doi:10.1016/j.autneu.2021.102859. PMID 34403981.
 |  |
